Growth hormone evaluation in duchenne muscular dystrophy

L. Merlini, C. Granata, A. Ballestrazzi, F. Cornelio, P. Tassoni, S. Tugnoli, E. Cacciari

Research output: Contribution to journalArticlepeer-review


Growth hormone (GH) release with pharmacological tests and sleep test, somatomedin C and auxological features were studied in 10 patients affected by Duchenne Muscular Dystrophy. GH release in these patients seems to be lower than normal; moreover some of them are of short stature without an evident relationship with GH deficit. The possible significance of the data obtained is discussed, particularly in relation to the clinical course of the disease, and to current therapeutic trials with a GH release inhibitor (mazindol).

Original languageEnglish
Pages (from-to)471-475
Number of pages5
JournalItalian Journal of Neurological Sciences
Issue number5
Publication statusPublished - Oct 1988


  • Duchenne muscular dystrophy
  • failure to thrive-mazindol
  • Growth hormone
  • somatomedin C

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Growth hormone evaluation in duchenne muscular dystrophy'. Together they form a unique fingerprint.

Cite this